William E. Frietze
AstraZeneca (United States)(US)
Publications by Year
Research Areas
Receptor Mechanisms and Signaling, Pharmacological Receptor Mechanisms and Effects, Neuropeptides and Animal Physiology, Chemical Synthesis and Analysis, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → MEK inhibitors: The chemistry and biological activity of U0126, its analogs, and cyclization products(1998)404 cited
- → Discovery of an Orally Active Series of Isoxazoline Glycoprotein IIb/IIIa Antagonists(1997)66 cited
- → Roles of UGT, P450, and Gut Microbiota in the Metabolism of Epacadostat in Humans(2016)42 cited
- → Orally Active Isoxazoline Glycoprotein IIb/IIIa Antagonists with Extended Duration of Action(1999)35 cited
- → CRF Ligands via suzuki and negishi couplings of 3-pyridyl boronic acids or halides with 2-benzyloxy-4-chloro-3-nitropyridine(2003)16 cited
- → 4-Piperidin-4-ylidenemethyl-benzamides as δ-opioid receptor agonists for CNS indications: Identifying clinical candidates(2011)10 cited
- → Multiparameter exploration of piperazine derivatives as δ-opioid receptor agonists for CNS indications(2011)6 cited
- → Efficient synthesis of a 7-azabicyclo[2.2.1]heptane based GlyT1 uptake inhibitor(2010)5 cited
- → Bicyclo((aryl)methyl)benzamides as inhibitors of GlyT1(2018)5 cited
- → N-(1-Arylpropionyl)-4-aryltetrahydropyridines, a new class of high-affinity selective .sigma. receptor ligands(1993)3 cited